| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Antibodies (therapeutic use)Immunological methods| 1 | 2005 | Recombinant bispecific antibodies for cancer therapy. | 
| + | - | nl | Acta Pharmacol Sin 26(1):1-9 (2005) Kontermann RE |
| 2 | 2009 | Immunotoxicity of monoclonal antibodies. |
| + | - | nl | MAbs 1(2):104-11 (2009) Descotes J |
| 3 | 2009 | Engineered CH2 domains (nanoantibodies). |
| + | - | nl | MAbs 1(1):26-8 (2009) Dimitrov DS |
| 4 | 1987 | The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer. |
| + | - | nl | Immunol Cell Biol 65 ( Pt 2)(-):111-25 (1987) |
| 5 | 2005 | Immunotoxins and cancer therapy. |
| + | - | nl | Cell Mol Immunol 2(2):106-12 (2005) Li Z |
| 6 | 2007 | Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. |
| + | - | nl | Cell Res 17(2):89-99 (2007) Zhang Q |
| 7 | 2009 | Antibody engineering to develop new antirheumatic therapies. |
| + | - | nl | Arthritis Res Ther 11(3):225 (2009) Isaacs JD |
| 8 | 2007 | Combination antibody-based cancer immunotherapy. |
| + | - | nl | Cancer Sci 98(9):1297-302 (2007) Takeda K |
| 9 | 2000 | New approaches to antibody therapy. |
| + | - | nl | Oncogene 19(53):6144-51 (2000) |
| 10 | 2001 | From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. |
| + | - | nl | Rheumatology (Oxford) 40(7):724-38 (2001) |
| 11 | 1991 | The advantage of protecting the antigen-binding site during antibody labeling. |
| + | - | nl | J Nucl Med 32(1):122-3 (1991) Krohn KA |
| 12 | 2003 | Anticancer antibodies. |
| + | - | nl | Am J Clin Pathol 119(4):472-85 (2003) |
| 13 | 2010 | New antibody conjugates in cancer therapy. |
| + | - | nl | ScientificWorldJournal 10(-):2070-89 (2010) |
| 14 | 2010 | The next generation of antibody-drug conjugates comes of age. |
| + | - | nl | Discov Med 10(53):329-39 (2010) |
| 15 | 2009 | Therapeutic antibodies: successes, limitations and hopes for the future. | 
| + | - | nl | Br J Pharmacol 157(2):220-33 (2009) Chames P |
| 16 | 2010 | Antibody validation. |
| + | - | nl | Biotechniques 48(3):197-209 (2010) |
| 17 | 2010 | Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. |
| + | - | nl | Clin Cancer Res 16(1):11-20 (2010) |
| 18 | 2002 | Radionuclide-antibody conjugates for single-cell cytotoxicity. |
| + | - | nl | Cancer 94(4 Suppl):1215-23 (2002) |
| 19 | 2002 | Choosing an optimal radioimmunotherapy dose for clinical response. |
| + | - | nl | Cancer 94(4 Suppl):1275-86 (2002) |
| 20 | 2009 | The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. |
| + | - | nl | Br J Cancer 101(11):1807-12 (2009) |
| 21 | 2009 | Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies. |
| + | - | nl | Antioxid Redox Signal 11(5):1123-37 (2009) |
| 22 | 2006 | Advances in cancer therapy with radiolabeled monoclonal antibodies. | 
| + | - | nl | Q J Nucl Med Mol Imaging 50(4):248-64 (2006) |
| 23 | 2004 | A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. |
| + | - | nl | Q J Nucl Med Mol Imaging 48(4):251-7 (2004) |
| 24 | 2004 | Design and manufacture of monoclonal antibodies for radioimmunotherapy. |
| + | - | nl | Q J Nucl Med Mol Imaging 48(4):258-66 (2004) |
| 25 | 2004 | Engineered single chain antibody fragments for radioimmunotherapy. |
| + | - | nl | Q J Nucl Med Mol Imaging 48(4):279-88 (2004) |
| 26 | 2004 | Radioimmunotherapy of prostate cancer. |
| + | - | nl | Q J Nucl Med Mol Imaging 48(4):297-304 (2004) |
